Brief: Adial Pharmaceuticals Inc - On August 31, Received Written Notice From Nasdaq Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Sept 2 (Reuters) - Adial Pharmaceuticals Inc ADIL.O :
* ADIAL PHARMACEUTICALS INC - ON AUGUST 31, RECEIVED
WRITTEN
NOTICE FROM NASDAQ OF DELISTING OR FAILURE TO SATISFY A
CONTINUED LISTING RULE OR STANDARD
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)